Multicenter study of efficacy and safety of subcutaneous foslevodopa/foscarbidopa treatment initiation or switch from LD/CD intestinal gel

被引：0
作者：
Morales-Casado, M.
Tabar-Comellas, G.
Gisbert-Tijeras, E.
Garcia-Melendez, D. D.
Dominguez-Bertalo, J.
Rivero-Rodriguez, D.
Lopez-Ariztegui, N.
机构：
来源：
MOVEMENT DISORDERS | 2024年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
872
引用
收藏
页码：S397 / S397
页数：1
相关论文
共 4 条
[1]   Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion [J].
Rosebraugh, Matthew ;
Liu, Wei ;
Neenan, Melina ;
Facheris, Maurizio F. .
JOURNAL OF PARKINSONS DISEASE, 2021, 11 (04) :1695-1702
[2]   Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease [J].
Rosebraugh, Matthew ;
Voight, Eric A. ;
Moussa, Ehab M. ;
Jameel, Feroz ;
Lou, Xiaochun ;
Zhang, Geoff G. Z. ;
Mayer, Peter T. ;
Stolarik, Deanne ;
Carr, Robert A. ;
Enright, Brian P. ;
Liu, Wei ;
Facheris, Maurizio F. ;
Kym, Philip R. .
ANNALS OF NEUROLOGY, 2021, 90 (01) :52-61
[3]  
Soileau MJ, 2023, LANCET NEUROL, V22, pE5, DOI 10.1016/S1474-4422(23)00048-0
[4]  
Soileau MJ, 2022, LANCET NEUROL, V21, P1099, DOI 10.1016/S1474-4422(22)00400-8
1